Compare FLGT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | REPL |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.4M | 781.3M |
| IPO Year | 2016 | 2018 |
| Metric | FLGT | REPL |
|---|---|---|
| Price | $28.05 | $7.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $28.33 | $12.00 |
| AVG Volume (30 Days) | 205.0K | ★ 1.2M |
| Earning Date | 02-27-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $315,549,000.00 | N/A |
| Revenue This Year | $16.84 | N/A |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.61 | N/A |
| 52 Week Low | $14.57 | $2.68 |
| 52 Week High | $31.04 | $14.80 |
| Indicator | FLGT | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 31.89 |
| Support Level | $27.56 | $7.87 |
| Resistance Level | $28.44 | $9.41 |
| Average True Range (ATR) | 0.71 | 0.49 |
| MACD | 0.18 | -0.20 |
| Stochastic Oscillator | 82.51 | 0.00 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.